AUS
NZ
UK
CA
USA
IND
Syntara has announced initial findings from its Phase 2a clinical trial of SNT-4728, aimed at isolated REM sleep behavior disorder (iRBD), a condition linked to Parkinson's disease. The update reveals statistically significant decreases in brain inflammation, suggesting promising prospects for early intervention in neurodegenerative disorders.
Key Points
- Company and ASX ticker: Syntara (SNT)
- Development update: Preliminary data from Phase 2a trial of SNT-4728
- Notable results: Statistically significant inflammation reduction in the putamen
- Investor outlook: Additional trial outcomes anticipated in Q3 2026
Phase 2a Trial Investigates iRBD as an Early Indicator of Parkinson's Disease
Syntara’s Phase 2a study targets patients diagnosed with isolated REM sleep behavior disorder (iRBD), frequently regarded as an early stage of Parkinson’s disease. The trial evaluates the effectiveness of SNT-4728 in diminishing brain inflammation, a critical factor in the advancement of neurodegenerative diseases.
Since over 70% of iRBD patients eventually develop Parkinson’s or related disorders, the trial aims to enable early intervention that could potentially delay disease progression.
Trial Structure and Participant Profile
This multi-center, placebo-controlled trial is conducted in Sydney, Australia, and Oxford, UK, enrolling 40 participants randomized in a 3:1 ratio to receive either SNT-4728 or placebo. Inclusion criteria required confirmed iRBD diagnosis and mild parkinsonism symptoms.
The median participant age is 68 years, predominantly male. The study successfully recruited a high-risk cohort, with 95% exhibiting misfolded alpha-synuclein in cerebrospinal fluid, indicating elevated risk for Parkinson’s conversion.
Primary and Secondary Outcomes Target Brain Inflammation
The primary endpoint measures changes in TSPO ligand binding via PET imaging within striato-cortical regions from baseline to week 12. Safety is assessed through adverse event monitoring and treatment adherence.
Secondary endpoints include TSPO ligand binding changes across additional subcortical and cortical regions and total distribution volume in global grey matter. Exploratory endpoints encompass clinical assessments and biomarkers pertinent to iRBD and neuroinflammation.
Safety and Adverse Event Profile
SNT-4728 demonstrated a favorable safety profile consistent with earlier Phase 2 studies. All 41 patients completed the randomized treatment phase without any serious adverse events.
A total of 125 treatment-emergent adverse events (TEAEs) were reported, all graded 1 or 2 in severity. Only 14 TEAEs were deemed related to treatment, with common side effects including headache, nasopharyngitis, and muscle spasms.
Notable Reduction in Putamen Inflammation
The study observed a statistically significant decrease in brain inflammation within the putamen, a region linked to motor symptoms of Parkinson’s disease. This effect was seen in 20 of 30 patients treated with SNT-4728, achieving a p-value of 0.0145.
No significant inflammation changes were noted in other brain regions or in the placebo group, underscoring the targeted impact of SNT-4728.
Implications for Early Parkinson’s Intervention
These preliminary findings indicate that SNT-4728 may be instrumental in early treatment strategies for Parkinson’s disease by addressing brain inflammation in iRBD patients, potentially slowing disease progression.
Given the significant unmet need in iRBD and related disorders, Syntara’s results could lead to novel therapeutic options emphasizing early diagnosis and intervention.
Upcoming Milestones and Outlook
Stakeholders will be attentive to forthcoming trial phases, with additional data expected in Q3 2026. Ongoing evaluation of SNT-4728’s efficacy and safety will be critical for assessing its commercial potential.
Syntara remains committed to advancing innovative treatments for neurodegenerative diseases, aiming to improve patient outcomes and influence the broader healthcare sector.
